Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri - Trial NCT01028690
Access comprehensive clinical trial information for NCT01028690 through Pure Global AI's free database. This phase not specified trial is sponsored by Centro Regional para el Estudio de las Enfermedades Digestivas and is currently status unknown. The study focuses on Helicobacter Pylori Infection,Dyspepsia. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centro Regional para el Estudio de las Enfermedades Digestivas
Timeline & Enrollment
N/A
Dec 01, 2009
Jan 01, 2012
Primary Outcome
Assessed decrease H. pylori gastric load by histology after 28 days compared to placebo and assessed by 13C-UBT before and after 28 days use of L. compared to placebo
Summary
Helicobacter pylori colonizes approximately to 50% of the world-wide population.
 
 There is an exigency to find routes alternating to control the infection with an ample
 perspective but without the complications of induction of resistance to antibiotics.
 Supplement dietetic with Lactobacillus reuteri (L. reuteri) in humans takes to the
 colonization of epithelium gastric and this, combined with the observation of which L.
 reuteri has the capacity to inhibit the growth of H. Pylori and its union to the gastric
 mucosa, indicates the potential that the native human bacteria control and influence in the
 colonization in humans.
 
 The acid-lactic bacteria (in particular the lactobacillus) have been studied by their effects
 in humans infected with H. Pylori with some success to reduce the load of bacteria Studies
 using supplements with L. reuteri as much in infected symptomatic patients as asymptomatic
 with H. pylori showed a clear reduction of the load of bacteria after 4 weeks of use and this
 was concordant with a reduction in the symptoms associated to the infection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01028690
Non-Device Trial